CN1882313A - 药物的薄荷醇溶液 - Google Patents

药物的薄荷醇溶液 Download PDF

Info

Publication number
CN1882313A
CN1882313A CNA2004800101740A CN200480010174A CN1882313A CN 1882313 A CN1882313 A CN 1882313A CN A2004800101740 A CNA2004800101740 A CN A2004800101740A CN 200480010174 A CN200480010174 A CN 200480010174A CN 1882313 A CN1882313 A CN 1882313A
Authority
CN
China
Prior art keywords
drug
menthol
bioavailability
metabolized
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800101740A
Other languages
English (en)
Chinese (zh)
Inventor
M·弗拉什纳-巴拉克
I·E·莱尔纳
V·罗森博格
N·莫尔达夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN1882313A publication Critical patent/CN1882313A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800101740A 2003-02-20 2004-02-17 药物的薄荷醇溶液 Pending CN1882313A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44924603P 2003-02-20 2003-02-20
US60/449,246 2003-02-20

Publications (1)

Publication Number Publication Date
CN1882313A true CN1882313A (zh) 2006-12-20

Family

ID=32908699

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800101740A Pending CN1882313A (zh) 2003-02-20 2004-02-17 药物的薄荷醇溶液

Country Status (10)

Country Link
US (1) US20040198646A1 (https=)
EP (1) EP1596832A2 (https=)
JP (1) JP2006524190A (https=)
KR (1) KR20050116368A (https=)
CN (1) CN1882313A (https=)
AU (1) AU2004212989A1 (https=)
CA (1) CA2516798A1 (https=)
EA (1) EA200501301A1 (https=)
MX (1) MXPA05008902A (https=)
WO (1) WO2004073686A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
US20060068015A1 (en) * 2003-10-10 2006-03-30 Per Holm Solid dosage form comprising a fibrate and a statin
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
JPWO2005094814A1 (ja) * 2004-03-31 2008-02-14 興和株式会社 外用剤
WO2006020984A2 (en) * 2004-08-13 2006-02-23 Teva Pharmaceutical Industries Ltd. Cyclosporin formulations
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
KR20070119700A (ko) * 2005-03-30 2007-12-20 테바 파마슈티컬 인더스트리즈 리미티드 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제
EA200701750A1 (ru) * 2005-03-30 2008-02-28 Тева Фармасьютикал Индастриес Лтд. Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер
CA2613875C (en) * 2005-07-04 2018-09-25 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US12576126B2 (en) 2019-09-09 2026-03-17 Taejoon Pharmaceutical Co., Ltd. Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
EP0910339B1 (en) * 1996-04-12 2005-02-02 Novadel Pharma Inc. Buccal polar spray
US20010049363A1 (en) * 1998-05-08 2001-12-06 Warner-Lambert Company Oral composition containing NSAIDs and essential oils
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
AU2003226021B2 (en) * 2002-03-26 2008-07-17 Teva Pharmaceutical Industries Ltd. Drug microparticles

Also Published As

Publication number Publication date
AU2004212989A1 (en) 2004-09-02
MXPA05008902A (es) 2005-10-05
WO2004073686A3 (en) 2004-11-04
CA2516798A1 (en) 2004-09-02
KR20050116368A (ko) 2005-12-12
EP1596832A2 (en) 2005-11-23
EA200501301A1 (ru) 2006-04-28
JP2006524190A (ja) 2006-10-26
US20040198646A1 (en) 2004-10-07
WO2004073686A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
HK1046277A1 (en) Benzamide formulation with histone deacetylase inhibitor activity
EP2101729A1 (en) Self-microemulsifying drug delivery systems
JP2009298823A (ja) 経口投与用ラパマイシン処方
JP2015145430A (ja) 薬剤の経口による生物学的利用能を向上させる方法及びより毒性の少ないオロチン酸塩組成物
CN1882313A (zh) 药物的薄荷醇溶液
TW200418495A (en) Use of CCI-779 in treatment of hepatic fibrosis
JP5404625B2 (ja) 組成物
US12156869B2 (en) Losartan liquid formulations and methods of use
JP2006524190A5 (https=)
CN1133424C (zh) 口服给药的雷怕霉素制剂
CN109496152B (zh) 癸氧喹酯组合物的肌肉内库存及其预防和治疗的方法
US8183287B2 (en) Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders
EP4313155A1 (fr) Formulation par voie orale d'ivermectine et utilisations
US20060141028A1 (en) Cyclosporin formulations
AU2008200464A1 (en) Menthol solutions of drugs
WO2003057198A1 (fr) Compositions pharmaceutiques a liberation modifiee
EP1260233A1 (en) P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
JPWO2001064253A1 (ja) P−糖蛋白修飾剤を配合する大腸送達用薬剤組成物
HK1157636A (en) Parenteral formulations of dopamine agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20061220